MEFENAMIC ACID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H15NO2
Molecular Weight	241.2851
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=CC(NC2=CC=CC=C2C(O)=O)=C1C

InChI

InChIKey=HYYBABOKPJLUIN-UHFFFAOYSA-N

InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C15H15NO2
Molecular Weight	241.2851
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23656341

Mefenamic acid is a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is used for the treatment of mild to moderate pain, including menstrual pain, inflammation, and fever. Clinical use of mefenamic acid has generally declined in an era where other NSAID use has flourished. While having modes of action and general toxicities similar to other NSAIDs, mefenamic acid, as a member of the fenamates, nevertheless possesses some unique in vitro effects that have the potential to distinguish this agent from others. Use of this drug remains relevant for pain syndromes and some gynecological disorders, albeit with considerable competition from other NSAIDs. New basic science has considerably improved the understanding of the biochemistry of mefenamic acid. As well as maintaining its use in traditional settings, there is a tremendous potential for expanding the application of mefenamic acid to niche roles. Mefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. Mefenamic acid concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because mefenamic acid is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-2 192 Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9626023	Inhibitor 8228		2.9 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 608 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf	Palliative		Approved 8360	PONSTEL Approved Use Mefenamic acid is indicated: For relief of mild to moderate pain in patients ≥ 14 years of age, when therapy will not exceed one week (7 days). For treatment of primary dysmenorrhea. Launch Date 3.78691191E11
Primary dysmenorrhea 16 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf	Palliative		Approved 8360	PONSTEL Approved Use Mefenamic acid is indicated: For relief of mild to moderate pain in patients ≥ 14 years of age, when therapy will not exceed one week (7 days). For treatment of primary dysmenorrhea. Launch Date 3.78691191E11

C_max

Value	Dose	Co-administered	Analyte	Population
5.91 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22116543/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		MEFENAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7942001/	2 mg/kg 1 times / day steady-state, oral dose: 2 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:		MEFENAMIC ACID plasma	Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
38.03 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22116543/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		MEFENAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.46 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22116543/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		MEFENAMIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
18.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7942001/	2 mg/kg 1 times / day steady-state, oral dose: 2 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:		MEFENAMIC ACID plasma	Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf	500 mg 1 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		MEFENAMIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg 1 times / day steady, oral (starting) Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf	Disc. AE: Gastrointestinal disorder NOS, Skin rash... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder NOS (severe) Skin rash Reaction skin (serious) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf

AEs

AE	Significance	Dose	Population
Skin rash	Disc. AE	500 mg 1 times / day steady, oral (starting) Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf
Reaction skin	serious Disc. AE	500 mg 1 times / day steady, oral (starting) Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf
Gastrointestinal disorder NOS	severe Disc. AE	500 mg 1 times / day steady, oral (starting) Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	substrate 1010

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
UGT2B7 146 UGT1A9 116 UGT1A3 84 UGT1A1 204 OAT4 145 OAT3 636 OAT1 595 OAT2 144

Drug as perpetrator

Target	Modality	Activity
UGT1A3 93	inhibitor 3240 Sources: https://www.tandfonline.com/doi/abs/10.1080/00498250310001602757	no
UGT2B7 157	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/17200831/ Page: 4.0	yes [IC50 0.3 uM]
OAT3 638	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490050/	yes [IC50 0.78 uM]
OAT1 599	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490050/	yes [IC50 0.83 uM]
OAT2 146	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490050/	yes [IC50 21.7 uM]
OAT4 145	inhibitor 3240 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490050/	yes [IC50 61.7 uM]
UGT1A1 254	inhibitor 3240 Sources: https://www.tandfonline.com/doi/abs/10.1080/00498250310001602757	yes [Inhibition 25 uM]
UGT1A9 121	inhibitor 3240 Sources: https://www.tandfonline.com/doi/abs/10.1080/00498250310001602757	yes [Inhibition 25 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2C9 1010	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf Page: 2.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:6717	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6717
ChemicalBook	CB5472051	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5472051
MolPort	MolPort-001-839-968	https://www.molport.com/shop/molecule-link/MolPort-001-839-968
Selleck Chemicals	mefenamic-acid	http://www.selleckchem.com/products/mefenamic-acid.html
ZINC	ZINC000000020241	http://zinc15.docking.org/substances/ZINC000000020241
eMolecules	591932	https://www.emolecules.com/cgi-bin/more?vid=591932

PubMed

Title	Date	PubMed
Letter: Aspirin sensitivity: other drugs.	1975 Feb	1115460
Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms.	1999 Jul 6	10393680
[A possible adverse effect from the association of losartan-mefenamic acid in hemodialysis].	2001	11385903
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.	2001	11228592
Clinical and pathological overlap in nonsteroidal anti-inflammatory drug-related small bowel diaphragm disease and the neuromuscular and vascular hamartoma of the small bowel.	2001 Apr	11257631
The first world report of botulinum A toxin injection for status migrainosus.	2001 Aug	11758858
MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis.	2001 Jan 26	11207363
Association of Dental Anaesthetists. Summer Scientific Meeting Stirling, Scotland 8-9 June, 2001. ADA meeting report.	2001 Jul	11862652
Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms.	2001 Mar	11181495
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.	2001 May-Jun	11386636
Growth and hematological studies on Brazilian children of low socioeconomic level.	2001 Sep	11791475
[A case of nonsteroidal anti-inflammatory drugs (NSAIDs) induced colitis].	2001 Sep	11579497
Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding.	2002	11869575
Protective role of vitamin E on mefenamic acid-induced alterations in erythrocytes.	2002 Aug	12223096
Bioactivity studies on beta-sitosterol and its glucoside.	2002 Aug	12203259
Describing solubility of polymorphs in mixed solvents by CNIBS/R-K equation.	2002 Dec	12561255
Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2).	2002 Jan	11858641
Characterization of mefenamic acid-guaiacol ester: stability and transport across Caco-2 cell monolayers.	2002 Jul	12180533
Simultaneous spectrophotometric determination of mefenamic acid and paracetamol in a pharmaceutical preparation using ratio spectra derivative spectrophotometry and chemometric methods.	2002 Jun 15	12049974
Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs.	2002 Nov	12388633
Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs.	2002 Oct 11	12147693
Tranexamic acid: a review of its use in the management of menorrhagia.	2003	12825966
Effects of anti-inflammatory drugs on convulsant activity of quinolones: a comparative study of drug interaction between quinolones and anti-inflammatory drugs.	2003 Dec	14691652
Multiple effects of mefenamic acid on K(+) currents in smooth muscle cells from pig proximal urethra.	2003 Dec	14623761
Comparison of fennel and mefenamic acid for the treatment of primary dysmenorrhea.	2003 Feb	12566188
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.	2003 Jan 1	12464242
Green tea catechins evoke a phasic contraction in rat aorta via H2O2-mediated multiple-signalling pathways.	2003 Jan-Feb	12542460
Vasopressin mediates neuroprotection in mice by stimulation of V1 vasopressin receptors: influence of PI-3 kinase and gap junction inhibitors.	2003 Jun	15266902
Investigations on mefenamic acid sustained release tablets with water-insoluble gel.	2003 May	12729834
Characterization of bropirimine O-glucuronidation in human liver microsomes.	2003 Oct	14555337
[Effect of acetylsalicylic and mefenamic acids on cytoarchitectonic of skin in rats with acute local cryogenic trauma].	2003 Sep-Oct	14650215
Peritoneal dialysis solutions contract arteries through endothelium-independent prostanoid pathways.	2004	15384822
Biological activity of five antibacterial flavonoids from Combretum erythrophyllum (Combretaceae).	2004 Aug	15234754
Epigallocatechin-3-gallate increases intracellular [Ca2+] in U87 cells mainly by influx of extracellular Ca2+ and partly by release of intracellular stores.	2004 Feb	14647974
Liquid chromatography method for determination of mefenamic acid in human serum.	2004 Feb 5	14698254
Physicochemical and crystallographic characterization of mefenamic acid complexes with alkanolamines.	2004 Jan	14648644
Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea.	2004 Jul	15225193
Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation.	2004 Jul 2	15117964
Rapid ESI-MS method for examining the thermal decomposition of pharmaceuticals.	2004 Jun	15124212
Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine.	2004 Jun 28	15222892
Factors associated with iron deficiency anemia in Brazilian preschool children.	2004 May-Jun	15192767
Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users.	2004 Oct	15451330

Patents

Sample Use Guides

In Vivo Use Guide

For the relief of acute pain in adults and adolescents ≥14 years of age, the recommended dose is 500 mg as an initial dose followed by 250 mg every 6 hours as needed, usually not to exceed one week. For the treatment of primary dysmenorrhea, the recommended dose is 500 mg as an initial dose followed by 250 mg every 6 hours, given orally, starting with the onset of bleeding and associated symptoms. Clinical studies indicate that effective treatment can be initiated with the start of menses and should not be necessary for more than 2 to 3 days.

Route of Administration: Oral

In Vitro Use Guide

Mefenamic acid (0-100 uM) exerted cytotoxic effects on oral squamous cell carcinoma (KB), osteogenic sarcoma (Saos-2), and human brain astrocytoma (1321N) cells, where the viability was approximately 75%. Malignant gliomas (U-87MG) cells were resistant to mefenamic acid.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:30:10 UTC 2023` Edited by `admin` on `Wed Jul 05 22:30:10 UTC 2023`
Record UNII	367589PJ2C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MEFENAMIC ACID

Official Name

English

GARDAN

Brand Name

English

M01AG01

Code

English

PONSTEL

Brand Name

English

N-2,3-Xylylanthranilic acid

Systematic Name

English

CI-473

Code

English

CN-35355

Code

English

MEFENAMATE

Common Name

English

MEFENAMIC ACID [EP MONOGRAPH]

Common Name

English

MEFENAMIC ACID [MART.]

Common Name

English

MEFENAMINIC ACID

Common Name

English

NSC-94437

Code

English

2-(2,3-DIMETHYLPHENYL)AMINOBENZOIC ACID

Systematic Name

English

BENZOIC ACID, 2-(2,3-DIMETHYLPHENYL)AMINO-

Common Name

English

MEFENAMIC ACID [VANDF]

Common Name

English

J2.344B

Code

English

MEFENAMIC ACID [MI]

Common Name

English

MEPHENAMIC ACID

Common Name

English

MEFENAMIC ACID [HSDB]

Common Name

English

MEFENAMIC ACID [USP MONOGRAPH]

Common Name

English

MEFENAMIC ACID [USAN]

Common Name

English

MEFENAMIC ACID [JAN]

Common Name

English

MEFENAMIC ACID [USP-RS]

Common Name

English

MEFENAMIC ACID [ORANGE BOOK]

Common Name

English

mefenamic acid [INN]

Common Name

English

Mefenamic acid [WHO-DD]

Common Name

English

INF-3355

Code

English

MEPHENAMINIC ACID

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000000160

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

NDF-RT

N0000175722

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

WHO-ATC

M01AG01

Created by admin on Wed Jul 05 22:30:10 UTC 2023 , Edited by admin on Wed Jul 05 22:30:10 UTC 2023

NCI_THESAURUS

C257

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

NDF-RT

N0000175721

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

WHO-VATC

QM01AG01

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

LIVERTOX

NBK548029

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

Code System Code Type Description

MESH

D008528

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

CAS

61-68-7

Created by admin on Wed Jul 05 22:30:10 UTC 2023 , Edited by admin on Wed Jul 05 22:30:10 UTC 2023

PRIMARY

ChEMBL

CHEMBL686

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

DAILYMED

367589PJ2C

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

ECHA (EC/EINECS)

200-513-1

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

WIKIPEDIA

MEFENAMIC ACID

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

RXCUI

257844

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

ALTERNATIVE

DRUG BANK

DB00784

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

EVMPD

SUB08703MIG

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

INN

1494

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

SMS_ID

100000091703

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

RS_ITEM_NUM

1379605

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

RXCUI

6693

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

RxNorm

NCI_THESAURUS

C47599

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

IUPHAR

2593

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

CHEBI

6717

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

MERCK INDEX

M7139

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

Merck Index

EPA CompTox

DTXSID5023243

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

HSDB

3115

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

PUBCHEM

4044

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

LACTMED

Mefenamic Acid

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

DRUG CENTRAL

1663

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

FDA UNII

367589PJ2C

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

NSC

94437

Created by admin on Wed Jul 05 22:30:11 UTC 2023 , Edited by admin on Wed Jul 05 22:30:11 UTC 2023

PRIMARY

Related Record Type Details


					4HZ67LW8L7

OAT-4

TRANSPORTER -> INHIBITOR


					ZWJ2Y6JZWY

OAT-3

TRANSPORTER -> INHIBITOR


					5840721PJZ

OAT-2

TRANSPORTER -> INHIBITOR

Amount:


					I81U7H57XI

OAT-1

TRANSPORTER -> INHIBITOR


					0M77ZW789J

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B7

METABOLIC ENZYME -> INHIBITOR

Comments:

inhibits pradigastat glucuronidation

Amount:

Related Record Type Details


					M3G76I0347

3-CARBOXY MEFENAMIC ACID ACYL-.BETA.-D-GLUCURONIDE

METABOLITE -> PARENT

Interaction Type:

MAJOR


					OX5H10G1RG

MEFENAMIC ACID GLUCURONIDE

METABOLITE -> PARENT

Interaction Type:

MAJOR


					53XT40J50Q

3-HYDROXYMETHYL MEFENAMIC ACID ACYL-.BETA.-D-GLUCURONIDE

METABOLITE -> PARENT

Interaction Type:

MAJOR


					LLA90H5KPK

3-CARBOXYMEFENAMIC ACID

METABOLITE -> PARENT


					8L4T2779IX

3-HYDROXYMETHYL MEFENAMIC ACID

METABOLITE -> PARENT

Related Record Type Details


					8SKN0B0MIM

Benzoic acid

IMPURITY -> PARENT

Comments:

Correction factors: for the calculation of contents, multiply the peak areas by 4.0

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					8P0867193V

O-CHLOROBENZOIC ACID

IMPURITY -> PARENT

Comments:

Correction factors: for the calculation of contents, multiply the peak areas by 5.9

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					ZD450ABI9X

2,3-XYLIDINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					U88XP2706B

2,3-DIMETHYL-N-PHENYLANILINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					3A84PG9047

N-(2,3-DIMETHYLPHENYL)-2-((2,3-DIMETHYLPHENYL)AMINO)BENZAMIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

Related Record Type Details


					367589PJ2C

MEFENAMIC ACID

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdfCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23656341

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23656341

C_max

T_1/2

F_unbound

Drug as perpetrator